Skip to main content
Erschienen in: Cancer Causes & Control 7/2019

17.05.2019 | Original Paper

Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network

verfasst von: Andrea N. Burnett-Hartman, J. David Powers, Jessica Chubak, Douglas A. Corley, Nirupa R. Ghai, Carmit K. McMullen, Pamala A. Pawloski, Andrew T. Sterrett, Heather Spencer Feigelson

Erschienen in: Cancer Causes & Control | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our objective was to describe differences in treatment patterns and survival between early-onset (< 50 years old) and late-onset colorectal cancer (CRC) patients in community-based health systems.

Methods

We used tumor registry and electronic health record data to identify and characterize patients diagnosed with adenocarcinoma of the colon or rectum from 2010 to 2014 at six US health systems in the patient outcomes to advance learning (PORTAL) network. We used logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) comparing the distribution of tumor characteristics and treatment patterns in early-onset versus late-onset CRC. Cox regression models were used to estimate adjusted hazard ratios (HRs) and CIs comparing survival between early- and late-onset CRC patients.

Results

There were 1,424 early-onset and 10,810 late-onset CRC cases in our analyses. Compared to late-onset CRC, early-onset CRC was significantly associated with advanced-stage disease, high-grade histology, signet ring histology, and rectal or left colon location. After adjusting for differences in tumor and patient characteristics, early-onset patients were more likely than late-onset patients to have > 12 lymph nodes examined (OR 1.60, CI 1.37–1.87), to receive systemic therapy (chemotherapy or immunotherapy) within 6 months of diagnosis (OR 2.84, CI 2.40–3.37), and to have a reduced risk of CRC-specific death (HR 0.66, CI 0.56–0.79).

Conclusions

Early-onset CRC is associated with aggressive tumor characteristics, distal location, and systemic therapy use. Despite some adverse risk factors, these patients tend to have better survival than older onset patients.
Literatur
7.
Zurück zum Zitat Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA (2018) Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. https://doi.org/10.3322/caac.21457 CrossRefPubMedPubMedCentral Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA (2018) Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. https://​doi.​org/​10.​3322/​caac.​21457 CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL (2016) Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA 315(23):2564–2575. https://doi.org/10.1001/jama.2016.5989 CrossRefPubMed Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL (2016) Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA 315(23):2564–2575. https://​doi.​org/​10.​1001/​jama.​2016.​5989 CrossRefPubMed
9.
Zurück zum Zitat Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ (2017) Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 112(7):1016–1030. https://doi.org/10.1038/ajg.2017.174 CrossRefPubMed Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ (2017) Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 112(7):1016–1030. https://​doi.​org/​10.​1038/​ajg.​2017.​174 CrossRefPubMed
10.
Zurück zum Zitat Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klapman JB, Larson DW, Lazenby AJ, Llor X, Lynch PM, Mikkelson J, Ness RM, Slavin TP Jr., Sugandha S, Weiss JM, Dwyer MA, Ogba N (2018) NCCN guidelines insights: colorectal cancer screening Version 1.2018. J Natl Compr Cancer Netw 16(8):939–949. https://doi.org/10.6004/jnccn.2018.0067 CrossRef Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klapman JB, Larson DW, Lazenby AJ, Llor X, Lynch PM, Mikkelson J, Ness RM, Slavin TP Jr., Sugandha S, Weiss JM, Dwyer MA, Ogba N (2018) NCCN guidelines insights: colorectal cancer screening Version 1.2018. J Natl Compr Cancer Netw 16(8):939–949. https://​doi.​org/​10.​6004/​jnccn.​2018.​0067 CrossRef
11.
Zurück zum Zitat Benson AB III, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D (2017) Colon cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(3):370–398CrossRefPubMed Benson AB III, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D (2017) Colon cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(3):370–398CrossRefPubMed
13.
15.
Zurück zum Zitat Weinberg BA, Marshall JL, Salem ME (2017) The growing challenge of young adults with colorectal cancer. Oncology (Williston Park) 31(5):381–389 Weinberg BA, Marshall JL, Salem ME (2017) The growing challenge of young adults with colorectal cancer. Oncology (Williston Park) 31(5):381–389
17.
Zurück zum Zitat O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY (2004) Do young colon cancer patients have worse outcomes? World J Surg 28(6):558–562CrossRefPubMed O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY (2004) Do young colon cancer patients have worse outcomes? World J Surg 28(6):558–562CrossRefPubMed
18.
Zurück zum Zitat O’Connell JB, Maggard MA, Livingston EH, Yo CK (2004) Colorectal cancer in the young. Am J Surg 187(3):343–348CrossRefPubMed O’Connell JB, Maggard MA, Livingston EH, Yo CK (2004) Colorectal cancer in the young. Am J Surg 187(3):343–348CrossRefPubMed
22.
Zurück zum Zitat Minardi AJ Jr, Sittig KM, Zibari GB, McDonald JC (1998) Colorectal cancer in the young patient. Am Surg 64(9):849–853PubMed Minardi AJ Jr, Sittig KM, Zibari GB, McDonald JC (1998) Colorectal cancer in the young patient. Am Surg 64(9):849–853PubMed
23.
Zurück zum Zitat Adkins RB Jr, DeLozier JB, McKnight WG, Waterhouse G (1987) Carcinoma of the colon in patients 35 years of age and younger. Am Surg 53(3):141–145PubMed Adkins RB Jr, DeLozier JB, McKnight WG, Waterhouse G (1987) Carcinoma of the colon in patients 35 years of age and younger. Am Surg 53(3):141–145PubMed
24.
Zurück zum Zitat D’Onofrio GM, Tan EG (1985) Is colorectal carcinoma in the young a more deadly disease? Aust N Z J Surg 55(6):537–540CrossRefPubMed D’Onofrio GM, Tan EG (1985) Is colorectal carcinoma in the young a more deadly disease? Aust N Z J Surg 55(6):537–540CrossRefPubMed
27.
Zurück zum Zitat Feigelson HS, McMullen CK, Madrid S, Sterrett AT, Powers JD, Blum-Barnett E, Pawloski PA, Ziegenfuss JY, Quinn VP, Arterburn DE, Corley DA (2017) Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv 11(3):393–400. https://doi.org/10.1007/s11764-017-0596-1 CrossRefPubMedPubMedCentral Feigelson HS, McMullen CK, Madrid S, Sterrett AT, Powers JD, Blum-Barnett E, Pawloski PA, Ziegenfuss JY, Quinn VP, Arterburn DE, Corley DA (2017) Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv 11(3):393–400. https://​doi.​org/​10.​1007/​s11764-017-0596-1 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, Wagner EH, Pardee R, Schmidt MM, Geiger A, Butani AL, Field T, Fouayzi H, Miroshnik I, Liu L, Diseker R, Wells K, Krajenta R, Lamerato L, Neslund Dudas C (2005) Building a virtual cancer research organization. J Natl Cancer Inst Monogr 35:12–25. https://doi.org/10.1093/jncimonographs/lgi033 CrossRef Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, Wagner EH, Pardee R, Schmidt MM, Geiger A, Butani AL, Field T, Fouayzi H, Miroshnik I, Liu L, Diseker R, Wells K, Krajenta R, Lamerato L, Neslund Dudas C (2005) Building a virtual cancer research organization. J Natl Cancer Inst Monogr 35:12–25. https://​doi.​org/​10.​1093/​jncimonographs/​lgi033 CrossRef
30.
Zurück zum Zitat Seiffert JE (1997) Development and use of the North American Association of Central Cancer Registries standards for cancer registries. Top Health Inf Manage 17(3):35–44PubMed Seiffert JE (1997) Development and use of the North American Association of Central Cancer Registries standards for cancer registries. Top Health Inf Manage 17(3):35–44PubMed
31.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
33.
Zurück zum Zitat Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 118(22):5614–5622. https://doi.org/10.1002/cncr.27593 CrossRefPubMedPubMedCentral Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 118(22):5614–5622. https://​doi.​org/​10.​1002/​cncr.​27593 CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN (2013) Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 119(8):1593–1601. https://doi.org/10.1002/cncr.27935 CrossRefPubMed Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN (2013) Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 119(8):1593–1601. https://​doi.​org/​10.​1002/​cncr.​27935 CrossRefPubMed
36.
Zurück zum Zitat Zhao H, Zhang N, Ho V, Ding M, He W, Niu J, Yang M, Du XL, Zorzi D, Chavez-MacGregor M, Giordano SH (2018) Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124(4):679–687. https://doi.org/10.1002/cncr.31094 CrossRefPubMed Zhao H, Zhang N, Ho V, Ding M, He W, Niu J, Yang M, Du XL, Zorzi D, Chavez-MacGregor M, Giordano SH (2018) Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124(4):679–687. https://​doi.​org/​10.​1002/​cncr.​31094 CrossRefPubMed
Metadaten
Titel
Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network
verfasst von
Andrea N. Burnett-Hartman
J. David Powers
Jessica Chubak
Douglas A. Corley
Nirupa R. Ghai
Carmit K. McMullen
Pamala A. Pawloski
Andrew T. Sterrett
Heather Spencer Feigelson
Publikationsdatum
17.05.2019
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 7/2019
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01181-3

Weitere Artikel der Ausgabe 7/2019

Cancer Causes & Control 7/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.